The SCHOOL of nature: II. Protein order, disorder and oligomericity in transmembrane signaling

Self/Nonself - Immune Recognition and Signaling

Volumn 1, Issue 2, 2010, Pages 89-102

  Sigalov, Alexander B ^a  

^a SignaBlok Inc   (United States)

Author keywords

Cell activation; Circular dichroism; Cytoplasmic homo interactions; Disorder to order transition; Folding; Homo oligomerization; Immune signaling; Intrinsic protein disorder; Intrinsically disordered proteins; Mechanistic model; MIRR; Multichain immune recognition receptors; Nuclear magnetic resonance; Protein oligomericity; Protein oligomerization; Protein order; Protein protein interactions; Receptor clustering; Receptor signaling; Receptor tyrosine kinases; SCHOOL model; Signaling chain homo oligomerization model; Single chain receptors; Transmembrane interactions

Indexed keywords

CELL SURFACE RECEPTOR; GLYCOPROTEIN VI; LIPID; MEMBRANE RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D;

AMINO ACID SEQUENCE; HYPOTHESIS; LIGAND BINDING; OLIGOMERIZATION; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING; RECOGNITION; REVIEW; SIGNAL TRANSDUCTION;

EID: 77954950381     PISSN: 19382030     EISSN: 19382049     Source Type: Journal    
DOI: 10.4161/self.1.2.11590     Document Type: Review

References (145)

1. Rudd CE. Disabled receptor signaling and new primary immunodeficiency disorders. N Engl J Med 2006; 354:1874-7.
2. Sigalov AB, ed. Multichain Immune Recognition Receptor Signaling: From Spatiotemporal Organization to Human Disease. New York: Springer-Verlag 2008; 357.
3. Klemm JD, Schreiber SL, Crabtree GR. Dimerization as a regulatory mechanism in signal transduction. Annu Rev Immunol 1998; 16:569-92.
4. Metzger H. Transmembrane signaling: the joy of aggregation. J Immunol 1992; 149:1477-87.
5. Iakoucheva LM, Brown CJ, Lawson JD, Obradovic Z, Dunker AK. Intrinsic disorder in cell-signaling and cancer-associated proteins. J Mol Biol 2002; 323:573-84.
6. Iakoucheva LM, Radivojac P, Brown CJ, O'Connor TR, Sikes JG, Obradovic Z, et al. The importance of intrinsic disorder for protein phosphorylation. Nucleic Acids Res 2004; 32:1037-49.
7. Minezaki Y, Homma K, Nishikawa K. Intrinsically disordered regions of human plasma membrane proteins preferentially occur in the cytoplasmic segment. J Mol Biol 2007; 368:902-13.
8. De Biasio A, Guarnaccia C, Popovic M, Uversky VN, Pintar A, Pongor S. Prevalence of intrinsic disorder in the intracellular region of human single-pass type I proteins: the case of the notch ligand Delta-4. J Proteome Res 2008; 7:2496-506.
9. Sigalov A, Aivazian D, Stern L. Homo-oligomerization of the cytoplasmic domain of the T cell receptor zeta chain and of other proteins containing the immunoreceptor tyrosine-based activation motif. Biochemistry 2004; 43:2049-61.
10. Sigalov AB, Aivazian DA, Uversky VN, Stern LJ. Lipid-binding activity of intrinsically unstructured cytoplasmic domains of multichain immune recognition receptor signaling subunits. Biochemistry 2006; 45:15731-9.
11. Sigalov AB, Zhuravleva AV, Orekhov VY. Binding of intrinsically disordered proteins is not necessarily accompanied by a structural transition to a folded form. Biochimie 2007; 89:419-21.
12. Uversky VN, Gillespie JR, Fink AL. Why are "natively unfolded" proteins unstructured under physiologic conditions? Proteins 2000; 41:415-27.
13. Le Gall T, Romero PR, Cortese MS, Uversky VN, Dunker AK. Intrinsic disorder in the protein data bank. J Biomol Struct Dyn 2007; 24:325-42.
14. Dunker AK, Brown CJ, Lawson JD, Iakoucheva LM, Obradovic Z. Intrinsic disorder and protein function. Biochemistry 2002; 41:6573-82.
15. Linding R, Jensen LJ, Diella F, Bork P, Gibson TJ, Russell RB. Protein disorder prediction: implications for structural proteomics. Structure 2003; 11:1453-9.
16. Ward JJ, McGuffin LJ, Bryson K, Buxton BF, Jones DT. The DISOPRED server for the prediction of protein disorder. Bioinformatics 2004; 20:2138-9.
17. Prilusky J, Felder CE, Zeev-Ben-Mordehai T, Rydberg EH, Man O, Beckmann JS, et al. FoldIndex: a simple tool to predict whether a given protein sequence is intrinsically unfolded. Bioinformatics 2005; 21:3435-8.
18. Oldfield CJ, Cheng Y, Cortese MS, Brown CJ, Uversky VN, Dunker AK. Comparing and combining predictors of mostly disordered proteins. Biochemistry 2005; 44:1989-2000.
19. Receveur-Brechot V, Bourhis JM, Uversky VN, Canard B, Longhi S. Assessing protein disorder and induced folding. Proteins 2006; 62:24-45.
20. Dyson HJ, Wright PE. Equilibrium NMR studies of unfolded and partially folded proteins. Nat Struct Biol 1998; 5:499-503.
21. Dyson HJ, Wright PE. Unfolded proteins and protein folding studied by NMR. Chem Rev 2004; 104:3607-22.
22. Dunker AK, Silman I, Uversky VN, Sussman JL. Function and structure of inherently disordered proteins. Curr Opin Struct Biol 2008; 18:756-64.
23. Dyson HJ, Wright PE. Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell Biol 2005; 6:197-208.
24. Vucetic S, Xie H, Iakoucheva LM, Oldfield CJ, Dunker AK, Obradovic Z, et al. Functional anthology of intrinsic disorder 2. Cellular components, domains, technical terms, developmental processes and coding sequence diversities correlated with long disordered regions. J Proteome Res 2007; 6:1899-916.
25. Xie H, Vucetic S, Iakoucheva LM, Oldfield CJ, Dunker AK, Obradovic Z, et al. Functional anthology of intrinsic disorder 3. Ligands, post-translational modifications and diseases associated with intrinsically disordered proteins. J Proteome Res 2007; 6:1917-32.
26. Xie H, Vucetic S, Iakoucheva LM, Oldfield CJ, Dunker AK, Uversky VN, et al. Functional anthology of intrinsic disorder 1. Biological processes and functions of proteins with long disordered regions. J Proteome Res 2007; 6:1882-98.
27. Gsponer J, Futschik ME, Teichmann SA, Babu MM. Tight regulation of unstructured proteins: from transcript synthesis to protein degradation. Science 2008; 322:1365-8.
28. Tompa P. The interplay between structure and function in intrinsically unstructured proteins. FEBS Lett 2005; 579:3346-54.
29. Uversky VN. What does it mean to be natively unfolded? Eur J Biochem 2002; 269:2-12.
30. Uversky VN, Dunker AK. Biochemistry. Controlled chaos. Science 2008; 322:1340-1.
31. Tompa P. Intrinsically unstructured proteins. Trends Biochem Sci 2002; 27:527-33.
32. Tompa P, Fuxreiter M. Fuzzy complexes: polymorphism and structural disorder in protein-protein interactions. Trends Biochem Sci 2008; 33:2-8.
33. Demchenko AP. Recognition between flexible protein molecules: induced and assisted folding. J Mol Recognit 2001; 14:42-61.
34. Dyson HJ, Wright PE. Coupling of folding and binding for unstructured proteins. Curr Opin Struct Biol 2002; 12:54-60.
35. Xu C, Gagnon E, Call ME, Schnell JR, Schwieters CD, Carman CV, et al. Regulation of T cell receptor activation by dynamic membrane binding of the CD3epsilon cytoplasmic tyrosine-based motif. Cell 2008; 135:702-13.
36. Aivazian DA, Stern LJ. Phosphorylation of T cell receptor zeta is regulated by a lipid dependent folding transition. Nat Struct Biol 2000; 7:1023-6.
37. Fong JH, Shoemaker BA, Garbuzynskiy SO, Lobanov MY, Galzitskaya OV, Panchenko AR. Intrinsic disorder in protein interactions: insights from a comprehensive structural analysis. PLoS Comput Biol 2009; 5:1000316.
38. Meszaros B, Tompa P, Simon I, Dosztanyi Z. Molecular principles of the interactions of disordered proteins. J Mol Biol 2007; 372:549-61.
39. Radhakrishnan I, Perez-Alvarado GC, Dyson HJ, Wright PE. Conformational preferences in the Ser133- phosphorylated and non-phosphorylated forms of the kinase inducible transactivation domain of CREB. FEBS Lett 1998; 430:317-22.
40. Richards JP, Bachinger HP, Goodman RH, Brennan RG. Analysis of the structural properties of cAMP- responsive element-binding protein (CREB) and phosphorylated CREB. J Biol Chem 1996; 271:13716-23.
41. Radhakrishnan I, Perez-Alvarado GC, Parker D, Dyson HJ, Montminy MR, Wright PE. Solution structure of the KIX domain of CBP bound to the transactivation domain of CREB: a model for activator:coactivator interactions. Cell 1997; 91:741-52.
42. Fletcher CM, McGuire AM, Gingras AC, Li H, Matsuo H, Sonenberg N, et al. 4E binding proteins inhibit the translation factor eIF4E without folded structure. Biochemistry 1998; 37:9-15.
43. Fletcher CM, Wagner G. The interaction of eIF4E with 4E-BP1 is an induced fit to a completely disordered protein. Protein Sci 1998; 7:1639-42.
44. Tomoo K, Matsushita Y, Fujisaki H, Abiko F, Shen X, Taniguchi T, et al. Structural basis for mRNA CapBinding regulation of eukaryotic initiation factor 4E by 4E-binding protein, studied by spectroscopic, X-ray crystal structural, and molecular dynamics simulation methods. Biochim Biophys Acta 2005; 1753:191-208.
45. Bourhis JM, Receveur-Brechot V, Oglesbee M, Zhang X, Buccellato M, Darbon H, et al. The intrinsically disordered C-terminal domain of the measles virus nucleoprotein interacts with the C-terminal domain of the phosphoprotein via two distinct sites and remains predominantly unfolded. Protein Sci 2005; 14:1975-92.
46. Zhou P, Lugovskoy AA, McCarty JS, Li P, Wagner G. Solution structure of DFF40 and DFF45 N-terminal domain complex and mutual chaperone activity of DFF40 and DFF45. Proc Natl Acad Sci USA 2001; 98:6051-5.
47. Demarest SJ, Martinez-Yamout M, Chung J, Chen H, Xu W, Dyson HJ, et al. Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators. Nature 2002; 415:549-53.
48. Singh VK, Pacheco I, Uversky VN, Smith SP, MacLeod RJ, Jia Z. Intrinsically disordered human C/EBP homologous protein regulates biological activity of colon cancer cells during calcium stress. J Mol Biol 2008; 380:313-26.
49. Danielsson J, Liljedahl L, Barany-Wallje E, Sonderby P, Kristensen LH, Martinez-Yamout MA, et al. The intrinsically disordered RNR inhibitor Sml1 is a dynamic dimer. Biochemistry 2008; 47:13428-37.
50. Lanza DC, Silva JC, Assmann EM, Quaresma AJ, Bressan GC, Torriani IL, et al. Human FEZ1 has characteristics of a natively unfolded protein and dimerizes in solution. Proteins 2009; 74:104-21.
51. Simon SM, Sousa FJ, Mohana-Borges R, Walker GC. Regulation of Escherichia coli SOS mutagenesis by dimeric intrinsically disordered umuD gene products. Proc Natl Acad Sci USA 2008; 105:1152-7.
52. Sigalov AB. Protein intrinsic disorder and oligomericity in cell signaling. Mol Biosyst 2010; 6:451-61.
53. Sigalov AB, Hendricks GM. Membrane binding mode of intrinsically disordered cytoplasmic domains of T cell receptor signaling subunits depends on lipid composition. Biochem Biophys Res Commun 2009; 389:388-93.
54. Duchardt E, Sigalov AB, Aivazian D, Stern LJ, Schwalbe H. Structure induction of the T-Cell receptor zeta-chain upon lipid binding investigated by NMR spectroscopy. Chembiochem 2007; 8:820-7.
55. Laczko I, Hollosi M, Vass E, Hegedus Z, Monostori E, Toth GK. Conformational effect of phosphorylation on T cell receptor/CD3zeta-chain sequences. Biochem Biophys Res Commun 1998; 242:474-9.
56. Gerlach H, Laumann V, Martens S, Becker CF, Goody RS, Geyer M. HIV-1 Nef membrane association depends on charge, curvature, composition and sequence. Nat Chem Biol 2010; 6:46-53.
57. Langner M, Kubica K. The electrostatics of lipid surfaces. Chem Phys Lipids 1999; 101:3-35.
58. Shoemaker SD, Vanderlick TK. Intramembrane electrostatic interactions destabilize lipid vesicles. Biophys J 2002; 83:2007-14.
59. Hazy E, Tompa P. Limitations of induced folding in molecular recognition by intrinsically disordered proteins. Chemphyschem 2009; 10:1415-9.
60. Sigalov AB, Kim WM, Saline M, Stern LJ. The intrinsically disordered cytoplasmic domain of the T Cell receptor zeta chain binds to the Nef protein of simian immunodeficiency virus without a disorder-to-order transition. Biochemistry 2008; 47:12942-4.
61. Mittag T, Kay LE, Forman-Kay JD. Protein dynamics and conformational disorder in molecular recognition. J Mol Recognit 2010; 23:105-16.
62. Schaefer TM, Bell I, Fallert BA, Reinhart TA. The T-cell receptor zeta chain contains two homologous domains with which simian immunodeficiency virus Nef interacts and mediates down-modulation. J Virol 2000; 74:3273-83.
63. Kuhns MS, Davis MM. The safety on the TCR trigger. Cell 2008; 135:594-6.
64. Blumenthal R, Clague MJ, Durell SR, Epand RM. Membrane fusion. Chem Rev 2003; 103:53-69.
65. Bullough PA, Hughson FM, Skehel JJ, Wiley DC. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 1994; 371:37-43.
66. Carr CM, Kim PS. A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell 1993; 73:823-32.
67. Hegyi H, Schad E, Tompa P. Structural disorder promotes assembly of protein complexes. BMC Struct Biol 2007; 7:65.
68. Espinoza-Fonseca LM. Reconciling binding mechanisms of intrinsically disordered proteins. Biochem Biophys Res Commun 2009; 382:479-82.
69. Kumar S, Ma B, Tsai CJ, Sinha N, Nussinov R. Folding and binding cascades: dynamic landscapes and population shifts. Protein Sci 2000; 9:10-9.
70. Tsai CJ, Ma B, Sham YY, Kumar S, Nussinov R. Structured disorder and conformational selection. Proteins 2001; 44:418-27.
71. Sigalov AB. Multichain immune recognition receptor signaling: different players, same game? Trends Immunol 2004; 25:583-9.
72. Sigalov AB. Immune cell signaling: a novel mechanistic model reveals new therapeutic targets. Trends Pharmacol Sci 2006; 27:518-24.
73. Sigalov AB. SCHOOL model and new targeting strategies. Adv Exp Med Biol 2008; 640:268-311.
74. Sigalov AB. Signaling chain homo-oligomerization (SCHOOL) model. Adv Exp Med Biol 2008; 640:121-63.
75. Sigalov AB. The SCHOOL of Nature I. Transmembrane Signaling. Self/Nonself 2010; 1.
76. Borg M, Mittag T, Pawson T, Tyers M, Forman-Kay JD, Chan HS. Polyelectrostatic interactions of disordered ligands suggest a physical basis for ultrasensitivity. Proc Natl Acad Sci USA 2007; 104:9650-5.
77. Keegan AD, Paul WE. Multichain immune recognition receptors: similarities in structure and signaling pathways. Immunol Today 1992; 13:63-8.
78. Sigalov A. Multi-chain immune recognition receptors: spatial organization and signal transduction. Semin Immunol 2005; 17:51-64.
79. Cooper JA, Qian H. A mechanism for SRC kinasedependent signaling by noncatalytic receptors. Biochemistry 2008; 47:5681-8.
80. Weiss A, Schlessinger J. Switching signals on or off by receptor dimerization. Cell 1998; 94:277-80.
81. Lemmon MA, Schlessinger J. Regulation of signal transduction and signal diversity by receptor oligomerization. Trends Biochem Sci 1994; 19:459-63.
82. Bennasroune A, Fickova M, Gardin A, Dirrig-Grosch S, Aunis D, Cremel G, et al. Transmembrane peptides as inhibitors of ErbB receptor signaling. Mol Biol Cell 2004; 15:3464-74.
83. Siegel RM, Muppidi JR, Sarker M, Lobito A, Jen M, Martin D, et al. SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane. J Cell Biol 2004; 167:735-44.
84. Uversky VN. Amyloidogenesis of natively unfolded proteins. Curr Alzheimer Res 2008; 5:260-87.
85. Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Annu Rev Biochem 2000; 69:373-98.
86. Zhou T, Mountz JD, Kimberly RP. Immunobiology of tumor necrosis factor receptor superfamily. Immunol Res 2002; 26:323-36.
87. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006; 24:99-146.
88. Jiang G, Hunter T. Receptor signaling: when dimerization is not enough. Curr Biol 1999; 9:568-71.
89. Marianayagam NJ, Sunde M, Matthews JM. The power of two: protein dimerization in biology. Trends Biochem Sci 2004; 29:618-25.
90. Chan FK. Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling. Cytokine 2007; 37:101-7.
91. Dosch DD, Ballmer-Hofer K. Transmembrane domainmediated orientation of receptor monomers in active VEGFR-2 dimers. Faseb J 2010; 24:32-8.
92. Geijtenbeek TB, Gringhuis SI. Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 2009; 9:465-79.
93. Krogsgaard M, Davis MM. How T cells 'see' antigen. Nat Immunol 2005; 6:239-45.
94. DeFranco AL. B-cell activation 2000. Immunol Rev 2000; 176:5-9.
95. Dal Porto JM, Gauld SB, Merrell KT, Mills D, PughBernard AE, Cambier J. B cell antigen receptor signaling 101. Mol Immunol 2004; 41:599-613.
96. Takai T. Fc receptors and their role in immune regulation and autoimmunity. J Clin Immunol 2005; 25:1-18.
97. Takai T. Fc receptors: their diverse functions in immunity and immune disorders. Springer Semin Immunopathol 2006; 28:303-4.
98. Colonna M, Nakajima H, Navarro F, Lopez-Botet M. A novel family of Ig-like receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells. J Leukoc Biol 1999; 66:375-81.
99. Borrego F, Kabat J, Kim DK, Lieto L, Maasho K, Pena J, et al. Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Mol Immunol 2002; 38:637-60.
100. Moroi M, Jung SM. Platelet glycoprotein VI: its structure and function. Thromb Res 2004; 114:221-33.
101. Barclay AN, Brown MH. The SIRP family of receptors and immune regulation. Nat Rev Immunol 2006; 6:457-64.
102. Kanazawa N, Tashiro K, Miyachi Y. Signaling and immune regulatory role of the dendritic cell immunoreceptor (DCIR) family lectins: DCIR, DCAR, dectin-2 and BDCA-2. Immunobiology 2004; 209:179-90.
103. Biassoni R, Cantoni C, Falco M, Pende D, Millo R, Moretta L, et al. Human natural killer cell activating receptors. Mol Immunol 2000; 37:1015-24.
104. Biassoni R, Cantoni C, Marras D, Giron-Michel J, Falco M, Moretta L, et al. Human natural killer cell receptors: insights into their molecular function and structure. J Cell Mol Med 2003; 7:376-87.
105. Aoki N, Kimura S, Xing Z. Role of DAP12 in innate and adaptive immune responses. Curr Pharm Des 2003; 9:7-10.
106. Bakker AB, Baker E, Sutherland GR, Phillips JH, Lanier LL. Myeloid DAP12-associating lectin (MDL)-1 is a cell surface receptor involved in the activation of myeloid cells. Proc Natl Acad Sci USA 1999; 96:9792-6.
107. van den Berg TK, Yoder JA, Litman GW. On the origins of adaptive immunity: innate immune receptors join the tale. Trends Immunol 2004; 25:11-6.
108. Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and signal integration. Nat Immunol 2006; 7:1266-73.
109. Takai T. Paired immunoglobulin-like receptors and their MHC class I recognition. Immunology 2005; 115:433-40.
110. Nakahashi C, Tahara-Hanaoka S, Totsuka N, Okoshi Y, Takai T, Ohkohchi N, et al. Dual assemblies of an activating immune receptor, MAIR-II, with ITAM-bearing adapters DAP12 and FcRgamma chain on peritoneal macrophages. J Immunol 2007; 178:765-70.
111. Fujimoto M, Takatsu H, Ohno H. CMRF-35-like molecule-5 constitutes novel paired receptors, with CMRF-35-like molecule-1, to transduce activation signal upon association with FcRgamma. Int Immunol 2006; 18:1499-508.
112. Stewart CA, Vivier E, Colonna M. Strategies of natural killer cell recognition and signaling. Curr Top Microbiol Immunol 2006; 298:1-21.
113. Reth M. Antigen receptor tail clue. Nature 1989; 338:383-4.
114. Songyang Z, Shoelson SE, Chaudhuri M, Gish G, Pawson T, Haser WG, et al. SH2 domains recognize specific phosphopeptide sequences. Cell 1993; 72:767-78.
115. Wu J, Cherwinski H, Spies T, Phillips JH, Lanier LL. DAP10 and DAP12 form distinct, but functionally cooperative, receptor complexes in natural killer cells. J Exp Med 2000; 192:1059-68.
116. Manolios N, Bonifacino JS, Klausner RD. Transmembrane helical interactions and the assembly of the T cell receptor complex. Science 1990; 249:274-7.
117. Call ME, Pyrdol J, Wiedmann M, Wucherpfennig KW. The organizing principle in the formation of the T cell receptor-CD3 complex. Cell 2002; 111:967-79.
118. Michnoff CH, Parikh VS, Lelsz DL, Tucker PW. Mutations within the NH2-terminal transmembrane domain of membrane immunoglobulin (Ig) M alters Igalpha and Igbeta association and signal transduction. J Biol Chem 1994; 269:24237-44.
119. Daeron M. Fc receptor biology. Annu Rev Immunol 1997; 15:203-34.
120. Feng J, Garrity D, Call ME, Moffett H, Wucherpfennig KW. Convergence on a distinctive assembly mechanism by unrelated families of activating immune receptors. Immunity 2005; 22:427-38.
121. Feng J, Call ME, Wucherpfennig KW. The assembly of diverse immune receptors is focused on a polar membrane-embedded interaction site. PLoS Biol 2006; 4:142.
122. Bakema JE, de Haij S, den Hartog-Jager CF, Bakker J, Vidarsson G, van Egmond M, et al. Signaling through mutants of the IgA receptor CD89 and consequences for Fc receptor gamma-chain interaction. J Immunol 2006; 176:3603-10.
123. Varin-Blank N, Metzger H. Surface expression of mutated subunits of the high affinity mast cell receptor for IgE. J Biol Chem 1990; 265:15685-94.
124. Stevens TL, Blum JH, Foy SP, Matsuuchi L, DeFranco AL. A mutation of the mu transmembrane that disrupts endoplasmic reticulum retention. Effects on association with accessory proteins and signal transduction. J Immunol 1994; 152:4397-406.
125. Zidovetzki R, Rost B, Pecht I. Role of transmembrane domains in the functions of B- and T-cell receptors. Immunol Lett 1998; 64:97-107.
126. Blum JH, Stevens TL, DeFranco AL. Role of the mu immunoglobulin heavy chain transmembrane and cytoplasmic domains in B cell antigen receptor expression and signal transduction. J Biol Chem 1993; 268:27236-45.
127. Ra C, Jouvin MH, Kinet JP. Complete structure of the mouse mast cell receptor for IgE (FcepsilonRI) and surface expression of chimeric receptors (ratmouse-human) on transfected cells. J Biol Chem 1989; 264:15323-7.
128. Schamel WW, Arechaga I, Risueno RM, van Santen HM, Cabezas P, Risco C, et al. Coexistence of multivalent and monovalent TCRs explains high sensitivity and wide range of response. J Exp Med 2005; 202:493-503.
129. Berlanga O, Bori-Sanz T, James JR, Frampton J, Davis SJ, Tomlinson MG, et al. Glycoprotein VI oligomerization in cell lines and platelets. J Thromb Haemost 2007; 5:1026-33.
130. Loregian A, Palu G. Disruption of protein-protein interactions: towards new targets for chemotherapy. J Cell Physiol 2005; 204:750-62.
131. Hershberger SJ, Lee SG, Chmielewski J. Scaffolds for blocking protein-protein interactions. Curr Top Med Chem 2007; 7:928-42.
132. Sillerud LO, Larson RS. Design and structure of peptide and peptidomimetic antagonists of protein-protein interaction. Curr Protein Pept Sci 2005; 6:151-69.
133. Sigalov AB. Transmembrane interactions as immunotherapeutic targets: lessons from viral pathogenesis. Adv Exp Med Biol 2007; 601:335-44.
134. Sigalov AB. New therapeutic strategies targeting transmembrane signal transduction in the immune system. Cell Adh Migr 2010; 4.
135. Sigalov AB. Novel mechanistic concept of platelet inhibition. Expert Opin Ther Targets 2008; 12:677-92.
136. Sigalov AB. Inhibiting Collagen-induced Platelet Aggregation and Activation with Peptide Variants. US 12/001,258 and PCT PCT/US2007/025389 patent applications filed on 12/11/2007 and 12/12/2007, respectively, claiming a priority to US 60/874,694 provisional patent application filed on 12/13/2006.
137. Sigalov AB. Novel mechanistic insights into viral modulation of immune receptor signaling. PLoS Pathog 2009; 5:1000404.
138. Wang XM, Djordjevic JT, Kurosaka N, Schibeci S, Lee L, Williamson P, et al. T-cell antigen receptor peptides inhibit signal transduction within the membrane bilayer. Clin Immunol 2002; 105:199-207.
139. Quintana FJ, Gerber D, Kent SC, Cohen IR, Shai Y. HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation. J Clin Invest 2005; 115:2149-58.
140. Sigalov AB. Interaction between HIV gp41 fusion peptide and T cell receptor: putting the puzzle pieces back together. Faseb J 2007; 21:1633-4.
141. Sigalov AB. More on: glycoprotein VI oligomerization: a novel concept of platelet inhibition. J Thromb Haemost 2007; 5:2310-2.
142. + T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions. Gastroenterology 2007; 132:2346-58.
143. + T cell-mediated colitis. Am J Physiol Gastrointest Liver Physiol 2008; 294:199-207.
144. Appel RD, Bairoch A, Hochstrasser DF. A new generation of information retrieval tools for biologists: the example of the ExPASy WWW server. Trends Biochem Sci 1994; 19:258-60.
145. Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol 1982; 157:105-32.